Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (20)
Other
- L2IP - Instituto de Pesquisas Clínicas — Brasília
- Hospital Universitario de Caxias do Sul — Caxias do Sul
- CPQuali Pesquisa Clínica Sao Paulo — São Paulo
- Yitzhak Shamir Medical Center — Beer Yaacov
Texas
- Dynamed Clinical Research, LP d/b/a DM Clinical Research — Houston
- La Providence Pediatrics Clinic - Chemidox Clinical Trials — Houston
- Martin Diagnostic Clinic — Tomball
Connecticut
- Yale School of Medicine - Yale Diabetes Center (YDC)) Trials — New Haven
- Stamford Therapeutics Consortium — Stamford
California
- Carey Chronis MD Pediatric, Infant and Adolescent Medicine — Ventura
Georgia
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics — Atlanta
Illinois
- Ann and Robert Lurie Children's Hospital of Chicago — Chicago
Louisiana
- Velocity Clinical Research — Lafayette
Mississippi
- Dynamed Clinical Research, LP d/b/a DM Clinical Research — Gulfport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06672549
The ClinicalTrials.gov registry entry for NCT06672549 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 704 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06672549 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Other, Texas, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06672549 about?
NCT06672549 is a clinical study titled "A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)". The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
What is the current status of trial NCT06672549?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2024-11-18. Estimated completion is 2027-03.
What conditions does trial NCT06672549 study?
This clinical trial studies the following conditions: Obesity, Overweight. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06672549?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06672549?
This trial is sponsored by Eli Lilly and Company, which has 704 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06672549 being conducted?
This trial has 20 study locations across California, Connecticut, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.